Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Iregene Therapeutics Ltd. currently faces 2 pending office actions within the Biotechnology & Pharmaceuticals sector. Both of these actions are assigned to 1 distinct examiner and 1 distinct art unit, concentrating the company's current legal hurdles. This arrangement means that the company's immediate prosecution success is tied to the specific determinations of a single technical group, which can simplify communication but increases the impact of that group's specific standards.
ROGERS, ERIC JASON is the busiest examiner, managing both of the 2 pending office actions. With only 1 distinct examiner and 1 distinct art unit involved, the company's 2 pending office actions are subject to a unified review process. This centralization requires a consistent approach to claim amendments and arguments across the 2 matters to satisfy the requirements of this specific examiner. The company must navigate the preferences of this 1 distinct examiner to advance its current interests in the biotechnology field, as this individual oversees all current pending actions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROGERS, ERIC JASON | 2 | 57.4% | +32.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18031877 | CHEMICAL CULTURE SYSTEM AND USE THEREOF | ROGERS, ERIC JASON | 21d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17999288 | SERUM-FREE INDUCTION METHOD FOR SENSORY NEURON CELL | ROGERS, ERIC JASON | 14d |
| 18031877 | CHEMICAL CULTURE SYSTEM AND USE THEREOF | ROGERS, ERIC JASON | 21d |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18031877 | CHEMICAL CULTURE SYSTEM AND USE THEREOF | ROGERS, ERIC JASON | 1638 | §103§112 | Final Rejection | 21d | Pending | Apr 14, 2023 |
| 17999288 | SERUM-FREE INDUCTION METHOD FOR SENSORY NEURON CELL | ROGERS, ERIC JASON | 1638 | §112 | Final Rejection | 14d | Pending | Jan 18, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial